hospitalpharmacyeurope . com | 2021 | 13 TABLE 1 FDA-approved biosimilars 2 Reference product Approval date Biosimilar drug name Manufacturer Commercially available Adalimumab ( Humira ) September 2016 Amjevita ( adalimumab-atto ) Amgen No August 2017 Cyltezo ( adalimumab-adbm ) Boehringer Ingelheim No October 2018 Hyrimoz ( adalimumab-adaz ) Sandoz No July 2019 Hadlima ( adalimumab-bwwd ) Samsung Bioepis No November 2019 Abrilada ( adalimumab-afzb ) Pfizer No July 2020 Hulio ( adalimumab-fkjp ) Mylan / Fujifilm Kyowa Kirin No Bevacizumab ( Avastin ) September 2017 Mvasi ( bevacizumab-awwb ) Amgen Yes June 2019 Zirabev ( bevacizumab-bvzr ) Pfizer Yes Epoetin-alfa ( Epogen ) May 2018 Retacrit ( epoetin alfa-epbx ) Hospira Yes Etanercept ( Enbrel ) August 2016 Erelzi ( etanercept-szzs ) Sandoz No April 2019 Eticovo ( etanercept-ykro ) Samsung Bioepis No Filgrastim ( Neupogen ) March 2015 Zarxio ( filgrastim-sndz ) Sandoz Yes July 2018 Nivestym ( filgrastim-aafi ) Hospira Yes Infliximab ( Remicade ) April 2016 Inflectra ( infliximab-dyyb ) Celltrion Yes May 2017 Renflexis ( infliximab-abda ) Samsung Bioepis Yes December 2017 Ixifi ( infliximab-qbtx ) Pfizer No December 2019 Avsola ( infliximab-axxq ) Amgen No Pegfilgrastim ( Neulasta ) June 2018 Fulphila ( pegfilgrastim-jmdb ) Mylan GmbH Yes November 2018 Udenyca ( pegfilgrastim-cbqv ) Coherus Yes November 2019 Ziextenzo ( pegfilgrastim-bmez ) Sandoz Yes June 2020 Nyvepria ( pegfilgrastim-apfg ) Pfizer No Rituximab ( Rituxan ) November 2018 Truxima ( rituximab-abbs ) Celltrion Yes July 2019 Ruxience ( rituximab-pvvr ) Pfizer Yes Trastuzumab ( Herceptin ) December 2017 Ogivri ( trastuzumab-dkst ) Mylan GmbH Yes December 2018 Herzuma ( trastuzumab-pkrb ) Celltrion Yes January 2019 Ontruzant ( trastuzumab-dttb ) Samsung Bioepis Yes March 2019 Trazimera ( trastuzumab-qyyp ) Pfizer Yes June 2019 Kanjinti ( trastuzumab-anns ) Amgen Yes